Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News bluebird bio Inc. BLUEV


Primary Symbol: BLUE

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:BLUEV)

Fundamentals Snapshot (NDAQ:BLUEV)

Current News (NDAQ:BLUE)

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

Business Wire 12 days ago

Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall

Business Wire September 12, 2022

bluebird bio Announces September Investor Events

Business Wire August 29, 2022

bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire August 17, 2022

bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire August 17, 2022

bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

Business Wire August 4, 2022

FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire June 10, 2022

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Business Wire June 9, 2022

bluebird bio stock trading halted today June 9th and tomorrow June 10th

Business Wire June 9, 2022

Bullboard Posts (NDAQ:BLUE)

RE:TD WATERHOUSE TOP 10 IN BIOTECHNOLOGY STOCKS

They should add EDT and SQD to their list .... like around the top. IMHO
inspecthrgadget - July 9, 2020

TD WATERHOUSE TOP 10 IN BIOTECHNOLOGY STOCKS

TD WATERHOUSE TOP 10 IN BIOTECHNOLOGY STOCKS Top 10 : 1.TRIL 2. BU 3. IBT 4. MDNA 5. APS 6. GENX 7. BLU 8. MBX 9. ARCH 10. MIR
TheBearInTheWoods - May 9, 2020

RE:RE:Amazing cure for bladder / brain cancer with laser tech

GRAMPS1996 - August 27, 2018

RE:Amazing cure for bladder / brain cancer with laser tech

An interesting Canadian company brother love. Difficult finding info. Found some news on yahoo.  Will keep an eye on it. 
norjase - August 27, 2018

Amazing cure for bladder / brain cancer with laser tech

I own many shares in Blue Bird Bio.  Similar company, which I must admit, appears to be developing better brain and bladder cancer...
Brotherlove - August 26, 2018

This stock sure looks like a Buy now to Target $120.00

 Complicated but do some research. This stock is at a value-inflection point and one can see a "slew of...
aebestacey - January 10, 2017